Medical researchers, including Fernando Fervenza, M.D., Ph.D., Mayo Clinic College of Medicine, recently reviewed kidney disease caused by genetic or acquired dysregulation of the complement alternative pathway (AP) in the Journal of the American Society of Nephrology.
Recent Stories for Research
It’s almost a crime the outside world doesn’t know about the human clinical trials occurring at Mayo Clinic’s Human Cell Therapy Laboratory in Rochester. Of the eleven (phase I) trials currently underway or just finishing, many are demonstrating promising results in treating chronic wounds, renal stenosis, and fatal neurological diseases such as amyotrophic lateral sclerosis and multiple-system atrophy.
A 65-year-old woman with congestive heart failure presented for a mitral valve replacement. She experienced excessive bleeding and thrombosis during surgery, with subsequent hemolytic anemia. Read this post to learn more about the case and the diagnosis.
Other Posts for Research
- The Effect of MALDI-TOF MS Reagents on Hazardous Bacteria
- Assessing Idiopathic Duct-Centric Chronic Pancreatitis
- Perioperative Morbidity of Cytoreductive Nephrectomy
- Prognostic and Bioepidemiologic Implications of Papillary Fibroelastomas
- The Importance and Implications of Newborn Screening for Lysosomal Storage Disorders
- Assessing the Genomic Landscape for Primary Central Nervous System Lymphomas
- Evaluation of cis-Regulatory Variation in Human Prostate Transcriptome
- Assessing Genetic Determinants in Momelotinib-Treated Patients with Myelofibrosis
- Glomerular C4d for Diagnosis of Proliferative Glomerulonephritis
- Examining Neuronal Pathology in Multiple System Atrophy